AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Leber Congenital Amaurosis

Recent research efforts aimed at curing Leber Congenital Amaurosis.

Last updated

Leber Congenital Amaurosis

Overview

Leber congenital amaurosis (LCA) is a group of rare inherited retinal disorders that cause severe visual impairment from birth or early infancy. It affects the retina’s light-sensing cells—rods and cones—and can involve many different genes, so the outlook varies substantially by genetic subtype. Children commonly have very limited vision, involuntary eye movements, poor responses to light, and absent or markedly reduced retinal electrical responses; some forms also cause disease outside the eye. GeneReviews overview

For most people, LCA has historically led to lifelong severe visual disability and progressive loss of remaining sight. Genetic testing is now central to diagnosis, prognosis, family counseling, and eligibility for gene-specific trials. The only U.S. FDA-approved disease-modifying treatment relevant to LCA is voretigene neparvovec-rzyl (Luxturna) for people with confirmed biallelic RPE65 mutation-associated retinal dystrophy and sufficient viable retinal cells. For other genetic forms, standard care remains low-vision rehabilitation, correction of refractive errors, management of complications, educational support, and monitoring for syndromic features. FDA Luxturna information GeneReviews management

Scope of Recent Research (2020–present)

Research activity has been unusually strong because LCA is often caused by a defect in a single gene and the eye permits local treatment and direct measurement of retinal function. From 2020 through October 20, 2026, the field has advanced beyond the established RPE65 therapy into gene supplementation for GUCY2D, AIPL1, and LCA5 disease, CRISPR editing for a common CEP290 mutation, and RNA medicines that alter abnormal CEP290 splicing. These advances represent genuine restoration of visual function in small studies, but they are not yet universal or proven permanent cures for the genetically diverse LCA population. LCA research and trials review Gene editing for CEP290 retinal degeneration

Major Breakthroughs and Emerging Therapies

Gene supplementation—delivering a working copy of a faulty gene with an adeno-associated virus (AAV)—has produced the strongest recent clinical evidence across several LCA subtypes. In GUCY2D-associated LCA1, the subretinal AAV5 therapy ATSN-101 was evaluated in 15 people in a phase 1/2 study. At the highest dose, treated eyes showed a mean 20.3-decibel improvement in dark-adapted full-field sensitivity testing at 12 months, versus 1.1 decibels in untreated fellow eyes; improvements emerged by day 28 and persisted through the first year. ATSN-101 phase 1/2 study

The most striking recent pediatric result is gene supplementation for AIPL1-associated LCA4. In a first-in-human UK study, four children aged 1.0 to 2.8 years received a single subretinal injection of AAV8 carrying AIPL1 in one eye. After a mean 3.5 years, treated eyes improved from near-light-perception-level vision before treatment to measurable functional visual acuity, while untreated eyes deteriorated; retinal structure was also relatively preserved in treated eyes. One treated eye developed cystoid macular edema, but investigators reported no other major safety concerns. AIPL1 gene therapy in children

A third gene-supplementation program, OPGx-001 for LCA5-associated disease, reported one-year results in 2025 from three adults treated with subretinal AAV8-LCA5. The phase 1b/2a study found no serious treatment- or procedure-related adverse events and reported approximately one log-unit average improvement in cone-mediated light sensitivity, supported by objective pupil testing and improved virtual-reality mobility performance. OPGx-001 one-year results

Gene editing has moved LCA into the CRISPR era. EDIT-101 uses an AAV5 vector to deliver CRISPR-Cas9 instructions intended to remove the abnormal splice signal caused by the common deep-intronic CEP290 IVS26 variant, allowing more normal CEP290 RNA to be made in photoreceptors. In the open-label phase 1/2 BRILLIANCE study, 14 participants received one subretinal dose; no treatment- or procedure-related serious adverse events or dose-limiting toxicities were reported. Nine participants had a clinically meaningful improvement in at least one prespecified vision outcome, although the small, uncontrolled study cannot establish the magnitude or durability of benefit. EDIT-101 clinical results EDIT-101 trial record

RNA therapy offers a non-permanent way to address the same common CEP290 splice defect. Sepofarsen is an antisense oligonucleotide—an engineered short strand of RNA-like material—given by injection into the vitreous to block erroneous inclusion of a pseudoexon in CEP290 RNA. In its 11-person phase 1b/2 study, visual-acuity and retinal-sensitivity improvements were reported, but cataracts requiring lens replacement occurred in six participants. The later randomized phase 2/3 ILLUMINATE study did not meet its 12-month visual-acuity primary endpoint, underscoring the uncertainty of early uncontrolled signals; nevertheless, Sepul Bio began dosing participants in a new phase 3 HYPERION trial in October 2025. Sepofarsen phase 1b/2 trial ILLUMINATE results update HYPERION trial launch

Small molecules and other mutation-independent approaches remain earlier-stage. For example, eupatilin improved cilia formation, cilia length, and rhodopsin trafficking in patient-derived CEP290 cells and retinal organoids, suggesting a possible strategy for people with diverse CEP290 variants rather than only the IVS26 splice variant. This is preclinical evidence, not a demonstrated human treatment. Eupatilin in CEP290 models

Clinical Trials and Experimental Approaches

The most informative recent completed or reported early-phase studies are ATSN-101 for GUCY2D-LCA1, EDIT-101 for CEP290-LCA10, AAV8-AIPL1 for LCA4, and OPGx-001 for LCA5 disease. ATSN-101, sponsored by Atsena Therapeutics, completed a phase 1/2 dose-escalation study in 15 participants and showed dose-related improvement in retinal sensitivity at 12 months. EDIT-101, sponsored by Editas Medicine, was a phase 1/2 open-label single-dose study in 14 participants; it established a first clinical proof of concept for in vivo CRISPR editing in the retina, but further development requires confirmation in larger studies. ATSN-101 phase 1/2 study EDIT-101 clinical results

The AIPL1 program was a non-randomized first-in-human intervention rather than a conventional commercial trial, developed by investigators at UCL and Moorfields with MeiraGTx participation. Its four-child dataset is exceptionally encouraging because the treated children were very young and had rapidly progressive disease, but its size means that longer follow-up and expansion to more patients are essential. AIPL1 gene therapy in children

For LCA5, Opus Genetics’ OPGx-001 remains in phase 1/2 development, with the published initial cohort providing a rationale for further dose escalation and testing in people with less advanced disease. Sepofarsen illustrates the value of rigorous controls: promising phase 1/2 findings did not translate into success on the original phase 2/3 primary endpoint, and the ongoing HYPERION phase 3 program will be an important test of whether revised trial design can demonstrate reproducible benefit. OPGx-001 one-year results ILLUMINATE results update HYPERION trial launch

Methodologies and Scientific Approaches

Researchers begin by defining the exact disease-causing variants through inherited-retinal-disease gene panels, exome sequencing, or genome sequencing. This is essential because a therapy that adds GUCY2D, corrects a specific CEP290 splice variant, or replaces AIPL1 will not treat unrelated LCA genes. Retinal imaging with optical coherence tomography (OCT), full-field stimulus testing, visual acuity, pupil responses, mobility tasks, and patient-reported visual function are then used to determine whether retinal cells remain present and whether treatment restores useful vision. GeneReviews overview ATSN-101 phase 1/2 study

Preclinical work increasingly combines patient-derived cells, induced pluripotent stem-cell retinal organoids, retinal explants, animal models, and viral-vector engineering. Organoids are especially useful for LCA10 because they reproduce photoreceptor-specific RNA-splicing and ciliary defects that may not be apparent in non-retinal cells. Researchers use these systems to test splice correction, gene-editing specificity, vector delivery, and the amount of restored protein needed before moving into patients. Eupatilin in CEP290 models EDIT-101 preclinical development

Leading Institutions and Funding

Major clinical and translational centers include the University of Pennsylvania and affiliated retinal research groups involved in GUCY2D and LCA5 studies; UCL Institute of Ophthalmology, Moorfields Eye Hospital, and Great Ormond Street Hospital in the AIPL1 pediatric program; and U.S. retinal centers participating in the EDIT-101 BRILLIANCE study. Key commercial developers include Atsena Therapeutics for ATSN-101, Opus Genetics for OPGx-001, Editas Medicine for EDIT-101, MeiraGTx in the AIPL1 program, and Sepul Bio for sepofarsen. ATSN-101 phase 1/2 study AIPL1 gene therapy in children EDIT-101 trial record

Funding is a mix of company-sponsored development and mission-driven support. The published AIPL1 study identified the UK National Institute for Health and Care Research and Moorfields Eye Charity as funders, while the ATSN-101 study was funded by Atsena Therapeutics. The Foundation Fighting Blindness also supports larger collaborative retinal-degeneration projects through Program Project Awards of up to $500,000 per year for as long as five years, a funding mechanism relevant to the complex, multi-institutional work needed for rare retinal diseases. AIPL1 gene therapy in children ATSN-101 phase 1/2 study Foundation Fighting Blindness Program Project Award

Strengths, Limitations, and Challenges

The field’s central strength is precision: several treatments directly address the molecular cause before all photoreceptors are lost, and the treated eye can often be compared with the untreated fellow eye. The strongest signals have come from gene supplementation in disorders where enough retinal structure remains, particularly early in childhood. The eye’s accessibility also enables local subretinal delivery and repeated functional and structural measurement. AIPL1 gene therapy in children ATSN-101 phase 1/2 study

The limitations are equally important. LCA is genetically heterogeneous, so a successful therapy for one subtype may help only a small number of people. Many studies remain small, open-label, and based on treated-eye versus untreated-eye comparisons; these designs can be informative in rare diseases but cannot fully exclude measurement variability, learning effects, or natural asymmetry. Surgery, retinal detachment risk, inflammation, immune responses, cataract formation, limited AAV carrying capacity for large genes, unknown long-term durability, and unequal access to specialized genetic testing and retinal-surgery centers remain substantial barriers. The sepofarsen phase 2/3 result demonstrates that early visual gains do not guarantee confirmatory-trial success. Sepofarsen phase 1b/2 trial ILLUMINATE results update LCA research and trials review

Outlook and Future Directions

LCA is closer to partial, genotype-specific restoration of vision than to a single universal cure. The next milestones are larger and longer studies confirming ATSN-101, expansion and durability data for AIPL1 and LCA5 gene supplementation, a clear development path for EDIT-101 or successor editing programs, and results from Sepul Bio’s HYPERION phase 3 sepofarsen study. The most plausible near-term future is a growing set of treatments matched to a person’s gene and residual retinal cells; a durable cure for all forms of LCA will require broader delivery systems, therapies for large or numerous genes, earlier diagnosis, and methods that can replace photoreceptors once degeneration is advanced. OPGx-001 one-year results HYPERION trial launch GeneReviews overview

References

Don't see your disease? Request a report